The latest advancement in
controlled release for liquids

Our strong commitment to R&D has yielded numerous innovations

Abuse deterrence technology for widely
used controlled substances and opiates

		Tris Pharma Announces Two NDA Approvals from FDA including a Pioneering, First-Ever 24 hour Liquid Sustained Release Product (Dec, 2009)
		FDA Accepts Tris Pharma's ANDA with Paragraph IV certification for a generic equivalent to Delsym (July, 2009)
		Tris Pharma Announces Acceptance of Its First Two NDAs (May, 2009)
		Tris Pharma's New Tool Fights Against Prescription Drug Abuse (November, 2008)
		Tris Pharma Completes Its Facilities' Expansion, Receives FDA Clearance (September, 2008)
		View more news...